Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
16 janv. 2025 07h30 HE
|
Ocugen
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs
14 janv. 2025 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose,...
Iantrek Announces First Commercial Cases of its C.Rex Micro-Interventional System for Trabecular Outflow Enhancement
13 janv. 2025 08h00 HE
|
Iantrek, Inc.
White Plains, NY., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc, a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional technologies for the...
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
13 janv. 2025 06h30 HE
|
Ocugen
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects...
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type
10 janv. 2025 09h35 HE
|
Research and Markets
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Diabetic Retinopathy - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report includes an...
Uveitis Global Clinical Trials Review 2024 | Now Available
10 janv. 2025 07h25 HE
|
Research and Markets
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Uveitis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the decision...
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
09 janv. 2025 08h30 HE
|
Alkeus Pharmaceuticals
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
08 janv. 2025 13h30 HE
|
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study,...
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
07 janv. 2025 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
06 janv. 2025 03h53 HE
|
Oculis Holding AG
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...